Literature DB >> 28810147

Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.

Dipongkor Saha1, Robert L Martuza1, Samuel D Rabkin2.   

Abstract

Glioblastoma is an immunosuppressive, fatal brain cancer that contains glioblastoma stem-like cells (GSCs). Oncolytic herpes simplex virus (oHSV) selectively replicates in cancer cells while inducing anti-tumor immunity. oHSV G47Δ expressing murine IL-12 (G47Δ-mIL12), antibodies to immune checkpoints (CTLA-4, PD-1, PD-L1), or dual combinations modestly extended survival of a mouse glioma model. However, the triple combination of anti-CTLA-4, anti-PD-1, and G47Δ-mIL12 cured most mice in two glioma models. This treatment was associated with macrophage influx and M1-like polarization, along with increased T effector to T regulatory cell ratios. Immune cell depletion studies demonstrated that CD4+ and CD8+ T cells as well as macrophages are required for synergistic curative activity. This combination should be translatable to the clinic and other immunosuppressive cancers.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HSV; cancer stem cells; glioma; immunotherapy; oncolytic virus

Mesh:

Substances:

Year:  2017        PMID: 28810147      PMCID: PMC5568814          DOI: 10.1016/j.ccell.2017.07.006

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  69 in total

1.  Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.

Authors:  Karishma Rajani; Christopher Parrish; Timothy Kottke; Jill Thompson; Shane Zaidi; Liz Ilett; Kevin G Shim; Rosa-Maria Diaz; Hardev Pandha; Kevin Harrington; Matt Coffey; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2015-08-27       Impact factor: 11.454

Review 2.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

Review 3.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

4.  CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.

Authors:  Dung T Le; Brian H Ladle; Timothy Lee; Vivian Weiss; Xiaosai Yao; Ashley Leubner; Todd D Armstrong; Elizabeth M Jaffee
Journal:  Int J Cancer       Date:  2010-11-12       Impact factor: 7.396

5.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

6.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Authors:  Hiroaki Wakimoto; Santosh Kesari; Christopher J Farrell; William T Curry; Cecile Zaupa; Manish Aghi; Toshihiko Kuroda; Anat Stemmer-Rachamimov; Khalid Shah; Ta-Chiang Liu; Deva S Jeyaretna; Jason Debasitis; Jan Pruszak; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

7.  Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Authors:  Jedd D Wolchok; James P Allison; Dmitriy Zamarin; Rikke B Holmgaard; Sumit K Subudhi; Joon Seok Park; Mena Mansour; Peter Palese; Taha Merghoub
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956

8.  Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model.

Authors:  David A Reardon; Prafulla C Gokhale; Sarah R Klein; Keith L Ligon; Scott J Rodig; Shakti H Ramkissoon; Kristen L Jones; Amy Saur Conway; Xiaoyun Liao; Jun Zhou; Patrick Y Wen; Annick D Van Den Abbeele; F Stephen Hodi; Lei Qin; Nancy E Kohl; Arlene H Sharpe; Glenn Dranoff; Gordon J Freeman
Journal:  Cancer Immunol Res       Date:  2015-11-06       Impact factor: 11.151

Review 9.  How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?

Authors:  Ole Audun Werner Haabeth; Anders Aune Tveita; Marte Fauskanger; Fredrik Schjesvold; Kristina Berg Lorvik; Peter O Hofgaard; Hilde Omholt; Ludvig A Munthe; Zlatko Dembic; Alexandre Corthay; Bjarne Bogen
Journal:  Front Immunol       Date:  2014-04-15       Impact factor: 7.561

Review 10.  Immunocompetent murine models for the study of glioblastoma immunotherapy.

Authors:  Taemin Oh; Shayan Fakurnejad; Eli T Sayegh; Aaron J Clark; Michael E Ivan; Matthew Z Sun; Michael Safaee; Orin Bloch; Charles D James; Andrew T Parsa
Journal:  J Transl Med       Date:  2014-04-29       Impact factor: 5.531

View more
  191 in total

1.  An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme.

Authors:  Yunyun Liu; Xiaoyu Li; Yuanpei Zhang; Hongxuan Wang; Xiongming Rong; Jialing Peng; Lei He; Ying Peng
Journal:  Oncogene       Date:  2019-08-19       Impact factor: 9.867

2.  Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.

Authors:  Wouter B L van den Bossche; Anne Kleijn; Charlotte E Teunissen; Jane S A Voerman; Cristina Teodosio; David P Noske; Jacques J M van Dongen; Clemens M F Dirven; Martine L M Lamfers
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 12.300

3.  CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.

Authors:  Joseph A Flores-Toro; Defang Luo; Adithya Gopinath; Matthew R Sarkisian; James J Campbell; Israel F Charo; Rajinder Singh; Thomas J Schall; Meenal Datta; Rakesh K Jain; Duane A Mitchell; Jeffrey K Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-26       Impact factor: 11.205

4.  PPP2R2B downregulation is associated with immune evasion and predicts poor clinical outcomes in triple-negative breast cancer.

Authors:  Zheng Li; Yaming Li; Xiaolong Wang; Qifeng Yang
Journal:  Cancer Cell Int       Date:  2021-01-06       Impact factor: 5.722

5.  Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.

Authors:  Mohammed Selman; Christopher Rousso; Anabel Bergeron; Hwan Hee Son; Ramya Krishnan; Nader A El-Sayes; Oliver Varette; Andrew Chen; Fabrice Le Boeuf; Fanny Tzelepis; John C Bell; Debbie C Crans; Jean-Simon Diallo
Journal:  Mol Ther       Date:  2017-10-24       Impact factor: 11.454

6.  Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.

Authors:  Hans-Georg Wirsching; Huajia Zhang; Frank Szulzewsky; Sonali Arora; Paola Grandi; Patrick J Cimino; Nduka Amankulor; Jean S Campbell; Lisa McFerrin; Siobhan S Pattwell; Chibawanye Ene; Alexandra Hicks; Michael Ball; James Yan; Jenny Zhang; Debrah Kumasaka; Robert H Pierce; Michael Weller; Mitchell Finer; Christophe Quéva; Joseph C Glorioso; A McGarry Houghton; Eric C Holland
Journal:  JCI Insight       Date:  2019-07-11

7.  Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.

Authors:  Catalina Lee-Chang; Aida Rashidi; Jason Miska; Peng Zhang; Katarzyna C Pituch; David Hou; Ting Xiao; Mariafausta Fischietti; Seong Jae Kang; Christina L Appin; Craig Horbinski; Leonidas C Platanias; Aurora Lopez-Rosas; Yu Han; Irina V Balyasnikova; Maciej S Lesniak
Journal:  Cancer Immunol Res       Date:  2019-09-17       Impact factor: 11.151

8.  Immunohistochemistry for Tumor-Infiltrating Immune Cells After Oncolytic Virotherapy.

Authors:  Dipongkor Saha; Samuel D Rabkin
Journal:  Methods Mol Biol       Date:  2020

9.  Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.

Authors:  Jinquan Cai; Qun Chen; Yuqiong Cui; Jiawei Dong; Meng Chen; Pengfei Wu; Chuanlu Jiang
Journal:  Oncoimmunology       Date:  2018-02-13       Impact factor: 8.110

10.  IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors.

Authors:  Sahil Gupta; Arpit Jain; Shahzad Nawaz Syed; Ryan G Snodgrass; Beatrice Pflüger-Müller; Matthias S Leisegang; Andreas Weigert; Ralf P Brandes; Ingo Ebersberger; Bernhard Brüne; Dmitry Namgaladze
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.